Navigation Links
Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula
Date:4/30/2009

(PHILADELPHIA) After surgery to remove the head of the pancreas, invagination of the pancreas into the small intestine resulted in a lower rate of pancreatic fistula, according to researchers at the Jefferson Pancreas, Biliary and Related Cancer Center. The research was published in the Journal of the American College of Surgeons. It was performed as a randomized trial the gold standard for studies.

Removing the head of the pancreas, a procedure called pancreaticoduodenectomy (PD), is a common treatment for benign and malignant pancreatic diseases. Pancreatic fistula, a leakage of pancreatic secretions, represents healing failure of the pancreatic reconnection. It is a common complication of PD, affecting approximately 20 percent of patients. The development of pancreatic fistula has been associated with several factors, including soft pancreas texture and surgical technique. It can result in prolonged hospitalization and other complications.

Prior to this study, the role of the type of pancreas-intestine reconnection procedure, known as pancreaticojejunostomy (PJ), in the development of pancreatic fistula had not been as well-studied , according to Adam Berger, M.D., associate professor in the department of Surgery of Jefferson Medical College at Thomas Jefferson University.

"We actually hypothesized that a duct-to-mucosa PJ procedure would result in fewer pancreatic fistulas," Dr. Berger said. "However, the rate of pancreatic fistula was almost double in patients who received the duct-to-mucosa PJ compared to the invagination PJ."

Dr. Berger and colleagues at Jefferson and Indiana University randomized 197 patients who were undergoing PD to receive either an invagination PJ or a duct-to-mucosa PJ. In the duct-to-mucosa cohort, the rate of pancreatic fistula was 24%. In the invagination cohort, the fistula rate was 12%. The greatest risk factor was pancreatic texture: 27% of patients with a soft gland developed pancr
'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Center to Expose and Close Animal Factories to Hold Media Teleconference Tomorrow to Discuss Smithfield Operations, Connection to Swine Flu, Health and Enviro Impacts
2. Meaningful Connections Offers Guidance, Case Examples for use of Electronic Health IT to Support Patient Centered Medical Home
3. Seniors Invited to Learn About Fraud Prevention at SCAN Connections Resource Center on April 28
4. American Cancer Society Launches Major Brand Revitalization Effort to Help Broaden Consumer Understanding and Connections
5. NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync
6. Migraine Poetry Contest Kicks Off at HealthCentrals MyMigraineConnection.com
7. Social Disconnection in African American Women With Breast Cancer
8. Selflessness, core of all major world religions, has neuropsychological connection
9. DaVita Inc. Announces Receipt of DOJ Subpoena in Connection with Previously Reported Investigation
10. Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets
11. Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4